Group 1 - The company, Marubi Biotechnology (603983.SH), announced a cash dividend distribution of 0.25 yuan per share (including tax), totaling 100 million yuan (including tax) based on a total share capital of 401 million shares prior to the distribution [1] - The record date for the dividend distribution is set for November 13, 2025, and the ex-dividend date is November 14, 2025 [1]

Market Overview - The cosmetics sector experienced a decline of 1.21% on November 6, with Betaini leading the drop [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] Individual Stock Performance - Notable gainers included: - Shuiyang Co., Ltd. (300740) with a closing price of 20.83, up 1.46% [1] - Qingsong Co., Ltd. (300132) with a closing price of 7.27, up 1.11% [1] - Significant decliners included: - Betaini (300957) with a closing price of 42.22, down 4.89% [2] - Jiahen Home Care (300955) with a closing price of 36.68, down 3.47% [2] Trading Volume and Capital Flow - The cosmetics sector saw a net outflow of 82.6352 million yuan from institutional investors, while retail investors had a net inflow of 58.2199 million yuan [2] - The trading volume for Shuiyang Co., Ltd. was 149,100 shares, with a transaction value of 311 million yuan [1] Capital Flow Analysis - Major net inflows were observed in: - Shuiyang Co., Ltd. with a net inflow of 23.1839 million yuan [3] - Qingsong Co., Ltd. with a net inflow of 7.1227 million yuan [3] - Major net outflows were noted in: - Betaini with a net outflow of 90.237 million yuan [3] - Shanghai Jahwa (600315) with a net outflow of 90.237 million yuan [3]

Core Viewpoint - The domestic beauty market in 2025 is experiencing a "growth cold wave," with many leading companies facing revenue declines or significantly slowed growth. However, Guangdong Marubi Biotechnology Co., Ltd. (Marubi) has reported impressive growth, achieving a 25.51% year-on-year increase in revenue for the first three quarters, making it one of the few companies in the industry to achieve both revenue and profit growth during this challenging period [2][3]. Industry Overview - The beauty industry is entering a competitive phase characterized by slow consumer recovery and peak channel benefits. Rational consumption has become mainstream, making growth for leading companies increasingly difficult [5]. - Among eight leading domestic beauty companies, four reported a year-on-year revenue decline, with three experiencing declines exceeding 10%. Marubi stands out with a significant revenue increase of 25.51% [8][9]. Financial Performance of Marubi - Marubi's revenue for the first three quarters reached 2.450 billion yuan, a year-on-year increase of 25.51%. In Q3 alone, revenue was 686 million yuan, up 14.28% year-on-year. The net profit attributable to shareholders was 244 million yuan, reflecting a year-on-year growth of 2.13% [11][12]. - The company's operating cash flow for the first three quarters was 1.589 billion yuan, a substantial increase of 132.19%, indicating that revenue growth is supported by actual sales collections [13]. Growth Drivers - Marubi's growth is attributed to internal factors rather than external market benefits, focusing on product, cost, and operational improvements. The company has optimized its product structure and upgraded to higher-end products, particularly in the eye care category, which saw a price increase of 52.83% year-on-year [14][16][18]. - The skincare category has become the primary revenue driver, contributing 306 million yuan in Q3, aligning with Marubi's strategy to transition from an eye care expert to a leader in comprehensive anti-aging solutions [19]. Cost Management and R&D - Marubi has implemented refined cost control through bulk purchasing and the use of quality domestic raw materials, enhancing profitability and pricing flexibility. The company has balanced marketing expenses and R&D investments, with sales expenses increasing by 32.09% and R&D expenses growing by 15.34% [20]. - The company has maintained a strong focus on technological innovation, receiving multiple awards and patents, which solidifies its competitive edge in the market [23]. Strategic Positioning - Marubi's strategic upgrades encompass brand positioning, technological development, and product matrix enhancements, providing sustained momentum for growth. The company has shifted its branding to emphasize anti-aging and has engaged well-known celebrities to enhance brand recognition [22][24]. - The company has achieved significant recognition in the market, being named the top brand in several product categories, which reflects its effective "R&D-product-market" closed-loop strategy [26][29]. Conclusion - Marubi's performance in Q3 2025 not only highlights its financial growth but also underscores its strategic advantages in product structure, operational efficiency, and market positioning. The company's transition from a marketing-driven to a technology-driven approach is crucial for sustaining competitive advantages in a challenging industry landscape [30].

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][32]. Core Insights - The report highlights the recent tax policy changes regarding gold, which exempts value-added tax for standard gold transactions, potentially boosting market activity [3][22]. - The beauty care sector shows mixed performance, with some companies reporting significant revenue growth while others face declines [4][25]. - The report emphasizes the importance of domestic brands in the beauty market, with notable rankings in the Douyin beauty list indicating a shift towards local products [22][23]. Market Performance - During the week of October 27 to October 31, 2025, the retail trade, social services, and beauty care sectors experienced changes of +1.63%, +0.45%, and -2.21% respectively, ranking 8th, 17th, and 30th among 31 primary industries [13][15]. - The cosmetics sector faced a decline of -2.57%, while segments like trade and e-commerce performed well with increases of +3.44% and +2.97% [15][18]. Key Company Announcements - Shanghai Jahwa reported a revenue of 4.961 billion yuan for the first three quarters of 2025, a year-on-year increase of 10.8%, with a net profit growth of 149.1% [25]. - Proya Cosmetics achieved a revenue of 7.098 billion yuan, reflecting a modest growth of 1.89% [25]. - The opening of Pop Mart's first store in the Middle East marks a significant expansion for the brand [29]. Investment Recommendations - The report suggests focusing on companies such as Shiseido, Giant Bio, Marubi, Runben, Proya, Chaohongji, and Furuida as potential investment targets within the recommended sectors [5][32].

Group 1: Industry Overview - The cosmetics retail sales in China grew by 3.9% year-on-year from January to September 2025, slightly underperforming the overall retail market by 0.6 percentage points, indicating a stable demand environment [4][14]. - Online platforms like Tmall and Douyin are experiencing a shift, with Tmall showing signs of recovery due to flash sales and member subsidies, while Douyin's growth has slightly slowed down [17][20]. - The demand for high-end and cost-effective products is increasing, while the mid-range segment is facing pressure due to a more conservative consumer environment [5][41]. Group 2: Competitive Landscape - The trend of domestic brands replacing foreign ones is slowing down, with leading foreign brands like L'Oréal and Estée Lauder showing signs of recovery in the Chinese market [23][24]. - The growth of domestic brands is becoming more differentiated, with some brands like Proya and Shiseido experiencing declines, while others like Youngor and Shanghai Jahwa continue to grow [23][24]. - The industry is witnessing an acceleration in the multi-brand matrix among leading companies, which is expected to increase market concentration [27][28]. Group 3: Key Companies - The report highlights several companies with strong growth potential, including Ruya Chen, Shumei Co., and Maogeping, which are expected to benefit from their brand strength and market positioning [3][54]. - Companies like Dekang Oral Care and Shanghai Jahwa are noted for their stable fundamentals and potential for marginal improvement, while others like Jinbo Biological and Huaxi Biological are anticipated to reach turning points [54]. - Ruya Chen's self-owned brand, Zhenjia, has shown significant growth, with a revenue increase of 345% year-on-year in Q3 2025, indicating strong brand development capabilities [60].

Investment Rating - The industry investment rating is "Outperform the Market" [1][22]. Core Insights - The report highlights that the liquor industry is experiencing a phase of accelerated clearing, with major companies like Kweichow Moutai showing resilience despite a slowdown in growth [1][4]. - The overall performance of the food and beverage sector has been mixed, with certain sub-sectors like pre-processed foods and snacks performing well, while soft drinks and other alcoholic beverages have seen declines [3][4]. - The report emphasizes the importance of focusing on high-quality companies with stable earnings during the industry's adjustment period, particularly recommending Kweichow Moutai and Shanxi Fenjiu for their strong fundamentals and attractive dividend yields [4]. Summary by Sections Liquor Industry - Kweichow Moutai reported Q3 2025 revenue of 39.064 billion yuan, a year-on-year increase of 0.56%, with net profit of 19.224 billion yuan, up 0.48% [3]. - The revenue from Moutai liquor increased by 7.26% to 34.924 billion yuan, while series liquor revenue fell by 34% [3]. - The company's gross margin improved to 91.44%, reflecting a better product mix, while net profit margin remained stable at 49.21% [3][4]. Dairy Industry - Yili Group's Q3 2025 revenue was 28.564 billion yuan, down 1.63%, with net profit of 3.226 billion yuan, a decrease of 3.35% [3]. - Liquid milk sales were under pressure, declining by 8.83%, while milk powder and dairy products saw a growth of 12.65% [3]. - The gross margin for Yili was 33.92%, down 1.13 percentage points, indicating cost pressures from raw milk prices [3]. Beauty Industry - Marubi Biotech achieved Q3 2025 revenue of 686 million yuan, up 14.28%, with net profit of 69 million yuan, an increase of 11.59% [4]. - The main brand Marubi saw a revenue increase of 33.93%, driven by strong performance of key products [4]. - The gross margin improved to 75.72%, supported by product mix optimization, despite increased marketing expenses [4].

Core Viewpoint - The cosmetics sector experienced a decline of 1.75% on November 4, with Marubi Biotechnology leading the drop [1][2] Group 1: Market Performance - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] - Major stocks in the cosmetics sector showed varied performance, with Qing Song Co. slightly up by 0.28% and Marubi Biotechnology down by 3.92% [1][2] Group 2: Trading Volume and Value - The trading volume and value for key stocks in the cosmetics sector were significant, with Qingdao Kingway recording a trading volume of 576,600 shares and a transaction value of 470 million yuan [2] - The total net outflow of main funds in the cosmetics sector was 208 million yuan, while retail investors saw a net inflow of 155 million yuan [2] Group 3: Fund Flow Analysis - The main funds showed a net outflow in several companies, including Marubi Biotechnology with a net outflow of 7.54 million yuan, while retail investors had a net inflow of 17.24 million yuan [3] - LaFang Co. had a net inflow of 8.17 million yuan from retail investors, despite a net outflow from main funds [3]

Core Viewpoint - Marubi Biotechnology faces regulatory scrutiny due to financial irregularities while simultaneously reporting a 25.51% revenue growth for Q3 2025, indicating a potential crisis management strategy to mitigate negative impacts from the regulatory warnings [1][7]. Financial Irregularities - The China Securities Regulatory Commission (CSRC) identified two main issues: non-compliance in financial accounting and improper management of raised funds [2][3]. - Specific financial accounting issues include inaccurate revenue recognition, misreporting of construction in progress, and incorrect classification of accounting items [2][3][6]. - The company reported inflated revenue of 4.55 million and net profit of 11.33 million for the first half of 2025, affecting the perceived quality of cash flow and financial strength [6]. Regulatory Actions - The Shanghai Stock Exchange and Guangdong Securities Regulatory Bureau issued corrective measures and warnings to key executives due to the identified financial irregularities [6][7]. - Marubi has committed to rectifying these issues and enhancing compliance awareness, although concerns about potential financial fraud remain [7]. Q3 2025 Performance - In Q3 2025, Marubi reported revenue of 685 million, a year-on-year increase of 14.28%, while net profit grew by 21.16% to 69.48 million [9]. - The company achieved a total revenue of 2.45 billion for the first three quarters, reflecting a 25.51% year-on-year growth, but the net profit only increased by 2.13% [9][10]. Market Position and Challenges - Marubi's performance indicates a troubling trend of "increased revenue without increased profit," highlighting potential weaknesses in core product competitiveness [10][12]. - The company has seen a decline in sales volume for its eye care products, with a significant reliance on price increases to drive revenue growth [12]. - Marketing expenditures have surged, with sales expenses rising from 795 million to 1.415 billion, while R&D spending remains relatively low [15][17]. Strategic Adjustments - Marubi is attempting to refocus its strategy by closing its Spring Diary brand's Tmall flagship store to concentrate resources on core business areas [17][18]. - Analysts predict that Marubi's annual revenue will remain between 3.7 billion and 3.9 billion, struggling to surpass the 4 billion threshold [18].

Summary of the Conference Call for Wanmei Biotechnology Company Overview - **Company**: Wanmei Biotechnology - **Industry**: Cosmetics and Skincare Key Financial Performance - **Revenue**: 2.44 billion CNY for the first three quarters of 2025, a year-on-year increase of 2.13% [2][3] - **Net Profit Margin**: 10% [2][3] - **Online Sales Proportion**: 87.71%, up 30.81% year-on-year, with Douyin direct sales growing by 37.25% [2][3] - **Offline Sales**: Decreased by 2.89% year-on-year [2][3] Brand Performance - **Perfect Brand Revenue**: 72.47% of total revenue, up 33.93% year-on-year [2][4] - **PL Yanhuo Brand Revenue**: 27.47% of total revenue, up 8.21% year-on-year [2][4] - **Product Categories**: Eye products grew by 57.03%, skincare by 27.25% [2][4] Strategic Adjustments - **Shift in Strategy**: Reduced reliance on influencer marketing (达播) and focused on self-broadcasting (自播), achieving 100% growth in self-broadcasting in Q3 [2][6] - **Future Goals**: Aim for sustained revenue and profit growth in Douyin by 2026 [2][6] Market Challenges - **Yanhuo Brand**: Facing challenges in a competitive makeup market, requiring more frequent new product launches [2][9] - **Investment in Medical Aesthetics**: Actively developing products related to restructured collagen and polysaccharides [2][9] Future Growth Projections - **Q4 Growth Expectation**: Anticipated growth exceeding double digits, with full-year growth expected to reach double digits [2][10] - **2026 Preparations**: Comprehensive preparations including team restructuring, product development, and marketing adjustments [2][10] External Investments - **Investment in New Brands**: Significant investments in emerging brands in skincare, oral care, and medical aesthetics, with a 25% stake in Shengzhirun [2][11] - **Strategic Partnerships**: Plans for strategic cooperation with Shengzhirun to launch ECM-related products [2][11] Competitive Landscape - **Response to International Brands**: Confidence in surpassing international brands due to advancements in R&D and strong consumer connections [2][12][13] - **Sales and Marketing Strategy**: Maintaining a focus on high-quality growth despite rising sales and traffic costs [2][13] Product and Marketing Highlights - **New Product Launches**: Successful limited series and upgraded product lines contributing to sales growth [2][14][15] - **Future Product Plans**: Introduction of new products including advanced sunscreen and high-end foundation [2][18][24][25] E-commerce Strategy - **GMV Distribution**: 55% from content e-commerce and 45% from shelf e-commerce, with Tmall accounting for 40% of shelf e-commerce [2][26] - **Team Structure**: 30% of the team focused on shelf e-commerce and 60% on content e-commerce [2][26] Internal Resource Allocation - **Brand Structure**: Two independent brands with separate supply chains and marketing teams [2][27] 2026 Development Goals - **Growth and Profit Targets**: Aiming for over 20% growth and a profit margin of 12% [2][28][29]

Core Viewpoint - Marubi Biotechnology (603983) reported a revenue of 686 million yuan for Q3 2025, reflecting a year-on-year growth of 14.28%, and a net profit attributable to shareholders of 69 million yuan, up 11.59% year-on-year [1] Group 1 - The company launched a significant new product, the "Super Mask," in April this year, which is currently in a rapid growth phase [1] - Continuous marketing investment and consumer awareness building are expected to drive the sales of this product [1] - The "Super Mask" is anticipated to become a core growth driver in Q4 and next year, following the success of previous products like the "Little Red Pen" and "Little Gold Needle" [1]